Evidence for depletion of brain DA, 5-HT and 5-HIAA concentrations following 3,4methylenedioxymethamphetamine (MDMA or "Ecstasy") administration in rats

Biogenic Amines

Volumn 13, Issue 6, 1997, Pages 525-535

  Dafters, R ^a   Yilmaz, B ^a   Gilmore, D P ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b Institute of Biomédical and Life Sciences   (United Kingdom)

Author keywords

5 HT and 5 hiaa; Dopamine; Ecstasy; MDMA neurotoxicity

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 5 HYDROXYINDOLEACETIC ACID; DOPAMINE; MONOAMINE; SEROTONIN;

5 HYDROXYINDOLEACETIC ACID BRAIN LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOSE RESPONSE; ELECTROCHEMICAL DETECTION; FRONTAL CORTEX; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPOCAMPUS; NEUROTOXICITY; NONHUMAN; RAT; SEROTONIN BRAIN LEVEL; SEROTONINERGIC NERVE CELL;

EID: 0030709418     PISSN: 01688561     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Battaglia, G., Zaczek, R. and De Souza, M (1990). In: Ecstasy: the Clinical, Pharmacological and NeuroloxicoloKical Kffecls of the Drug MDMA.
2. Colado, M.I., Williams, J.L. and Green, A.R. (1995). The hyperthermic and neurotoxic effects of "Ecstasy" (MDMA) and 3,4-meUiylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metnbolizer phenotype. Brit J Pharnwcol, 115:1281 -1289.
3. Commins, D.L., Axt, K.J., Vosmer, G. and Seiden, L.S. (1987). 5,6-dihydroxytryptamine, a serotonergic neurotoxin is formed endogenously in the rat brain. Brain Res, 403: 7-14.
4. Dafters, R.I. (1994). Effects of ambient temperature on hyperthermia and hyperkinesis induced by 3,4-methyIenedioxymethamphetamine (MDMA or "Ecstasy") in rats. Psychopharmacology, 114:505-508.
5. Fischer, C., Hatzidimitriou, G., Wios, J., Katz, J. and Ricaurte, G. (1995). / Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug MDMA. J Neurosci, 15: 5476-5485.
6. Gordon, C.J., Wilkinson, W.P., O'Callaghan, J.P. and Miller, D.B. (1991). Effect of 3,4-methylenedioxymethamphetamine on autonomie thermoregulatory responses of the rat. Pharnwcol Biochem Behav, 38: 339-344.
7. Green, R.A., Cross, A.J. and Goodwin, G.M. (1995). Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy"). Psychopharmacology, 119: 247-260.
8. Henry, J.A., Jeffreys, K.J. and Dawling, S. (1992). Toxicity and deaths from 3,4 methylenedioxymethamphetamine ("Ecstasy"). Lancet, 340:384-387.
9. Johnson, M.P., Elayan, I., Hanson, G.R., Foltz, R.L., Gibb, J.W. and Lim, H.K. (1992). Effects of 3,4-dihydroxymethamphetamine and 2,4,5 trihydroxymethamphetamine, two metaboliles of 3,4-methylenedioxymethamphetamine on central serotonergic and dopaminergic systems. J Pharm Exp Ther, 261: 447-453.
10. Kelland, M.D., Freeman, A.S. and Chiodo, L.A. (1989). +/- 3,4-Methylenedioxymethamphctamine-induced changes in the basal activity and pharmacological responsiveness of nigrostriatal dopamine neurons. Eur J Pharm, 169: 11-21.
11. Lim, U.K. and Foltz, R.L. (1991). Ion trap mass spectrometric evidence for the metabolism of 3,4-methylcnedioxymethamphetamine to the potent neurotoxins 2,4,5-DHMA and 2,4,5-DIIA. Clum Res Toxicol. 4: 626-632.
12. McCann, U.D. and Ricaurte, G.A. (1991). Lasting neuropsychiatrie sequelae of +-3,4 melhylenedioxymethamphetaminc ("Ecstasy") in recreational users. J Clin Psychophannacol. 11: 302-305.
13. Miller, D.D. and O'Callaghan, J.P. (1994). Environment-, drug- and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL/6J mouse../ Pharm Exp Ther, 270: 752-760.
14. O'Callaghan, J.P. and Miller, D.B. (1994). Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J Pharm Exp Ther, 270: 741-751.
15. Molliver, M.E., O'Heam, E., Battaglia, G. and De Souza, E.B. (1986). Direct intracerebral administrations of MDA and MDMA does not produce serotonergic neurotoxicity. Soc. Neurosci. Abst. 12: p 1234.
16. Paris, J.M. and Cunningham, K.A. (1992). Lack of serotonin neurotoxicity after intraraphe microinjection of 3,4-methylenedioxymethamphetamine. Brain Res Bull, 28: 115-119.
17. Ricaurte, O.A., Forno, L.S., Wilson, M.A., De Lanney, L.E., Irwin, L, Molliver, M.E. and Langston, J.W. (1988). MDMA selectively damages central serotonergic neurons in the primate. JAMA, 260:51-55.
18. Schmidt, C.J. (1987). Neurotoxicity of the psychedelic ampheLimine, methylenedioxy methamphetamine. J Pharm Exp Tlier, 240: 1-7.
19. Schmidt, C.J., Wu, L. and Lovenberg, W. (1986). MDMA: a potentially neurotoxic amphetamine analogue. Eur J Pharm. 124: 175-178.
20. Schmidt, C.J., Lewin, J.A. and Lovenberg, W. (1987). In vitro and in vivio effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain. Biochem Pharmacol, 36: 747-755.
21. Schmidt, C.J., Black, C.K. and Taylor, V.L. (1991). L-Dopa potentiation of serotonergic deficits due to a single administration of 3,4methylenedioxymethamphetamine, p-chloroamphetamine or methamphetamine to rats. Eur J Pharm, 203: 41-49.
22. Stone, D.M., Stahl, D.C., Hanson., G.R. and Gibb, J.W. (1986). Effects of 3,4methylenedioxymethamphetamine on tyrosine hydroxylase activity in the rat brain. Fed Proc, 45: 106.
23. Stone, D.M., Johnson, M., Hanson, G.R. and Gibb, J.W. (1988). Role of endogenous dopamine in central serotonergic deficits induced by 3,4methylenedioxymethamphetamine. .7 Pluirm Exp Ther, 247: 79-87.
24. Yamamoto, B. K. and Spanos, L. J. (1988). The acute effects of methylenedioxymethamphetamine on dopaminc release in the awake-behaving rat. Eur J Pharm, 148: 195-203.
25. Yilmaz, B., Gilmore, O.P. and Wilson C.A. (1996). Inhibition of the pre-ovulatory LII surge in the rat by central noradrenergic mediation: Involvement of an anaesthetic (urethane) and opioid receptor agonists. Riogenic Amines, 12: 423-435.